Evidence map›Paper›PMID 37143823›Full record

ArticleFrontiers in molecular biosciences2023

Discovery of a cryptic pocket in the AI-predicted structure of PPM1D phosphatase explains the binding site and potency of its allosteric inhibitors.

Artur Meller, Saulo De Oliveira, Aram Davtyan, Tigran Abramyan, Gregory R Bowman, Henry van den Bedem

Abstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Ligand-driven modulation of chaperone-cochaperone networks shapes proteostasis outcomes.Protein science : a publication of the Protein Society · 2026
    Article
  3. Review
  4. Review
  5. RiSKs in Computational Modeling of Isoform-Selective RSK Inhibitors.Journal of chemical information and modeling · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. A journey from molecule to physiology andFrontiers in pharmacology · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Artur MellerDepartment of Biochemistry and Molecular Biophysics, Washington University in St. Louis, St. Louis, MO, United States.
Saulo De OliveiraAtomwise, Inc., San Francisco, CA, United States.
Aram DavtyanAtomwise, Inc., San Francisco, CA, United States.
Tigran AbramyanAtomwise, Inc., San Francisco, CA, United States.
Gregory R BowmanDepartment of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, United States.
Henry van den BedemAtomwise, Inc., San Francisco, CA, United States.

Funding

MSMs, adaptive sampling, and data sharing on the cloudR01GM124007 · NIGMS · WASHINGTON UNIVERSITY · PI BOWMAN, GREGORY · 2017 to 2021
$2.0M
Structural basis for ApoE4-induced Alzheimer's diseaseRF1AG067194 · NIA · WASHINGTON UNIVERSITY · PI BOWMAN, GREGORY · 2021 to 2021
$1.8M
Modeling Hidden Myosin Structural States to Predict Drug Specificity and Disease PhenotypesF30HL162431 · NHLBI · WASHINGTON UNIVERSITY · PI MELLER, ARTUR · 2022 to 2025
$141k
NHLBI NIH HHS F30 HL162431NIA NIH HHS RF1 AG067194NIGMS NIH HHS R01 GM124007
6 · The paper itself

Abstract

Virtual screening is a widely used tool for drug discovery, but its predictive power can vary dramatically depending on how much structural data is available. In the best case, crystal structures of a ligand-bound protein can help find more potent ligands. However, virtual screens tend to be less predictive when only ligand-free crystal structures are available, and even less predictive if a homology model or other predicted structure must be used. Here, we explore the possibility that this situation can be improved by better accounting for protein dynamics, as simulations started from a single structure have a reasonable chance of sampling nearby structures that are more compatible with ligand binding. As a specific example, we consider the cancer drug target PPM1D/Wip1 phosphatase, a protein that lacks crystal structures. High-throughput screens have led to the discovery of several allosteric inhibitors of PPM1D, but their binding mode remains unknown. To enable further drug discovery efforts, we assessed the predictive power of an AlphaFold-predicted structure of PPM1D and a Markov state model (MSM) built from molecular dynamics simulations initiated from that structure. Our simulations reveal a cryptic pocket at the interface between two important structural elements, the flap and hinge regions. Using deep learning to predict the pose quality of each docked compound for the active site and cryptic pocket suggests that the inhibitors strongly prefer binding to the cryptic pocket, consistent with their allosteric effect. The predicted affinities for the dynamically uncovered cryptic pocket also recapitulate the relative potencies of the compounds (τ

Indexed as

allosteric inhibitioncryptic sitedeep learningmarkov state modelsmolecular dynamics simulationvirtual high throughput screening (vHTS)

Identifiers

PMID37143823
PMCPMC10151774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.